LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
